Viewing Study NCT07104032


Ignite Creation Date: 2025-12-24 @ 9:34 PM
Ignite Modification Date: 2026-06-21 @ 9:05 AM
Study NCT ID: NCT07104032
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-11-21
First Post: 2025-07-29
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)
Sponsor: Ono Pharmaceutical Co. Ltd
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsed/Refractory Primary Central Nervous System Lymphoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Bruton's tyrosine kinase (BTK) View